Phase I trial of KX 02 in Chinese patients with brain tumours.

Trial Profile

Phase I trial of KX 02 in Chinese patients with brain tumours.

Planning
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs KX 02 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Xiangxue Pharmaceutical
  • Most Recent Events

    • 24 May 2017 According to an Athenex media release, its partner, Guangzhou Xiangxue Pharmaceutical Co. Ltd., (Xiangxue) has received the Chinese FDA Investigational New Drug (IND) approval to begin clinical trials for KX-02 tablet for glioblastoma in May 2017 under the Class 1 New Drug Regulation in China.
    • 30 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top